R&D

April, 2023

S095029: a novel clinical-stage Fc-silenced NKG2A-blocking antibody with best-in-class potential

Melander M, Laugel B.
In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Cancer Res (2023) 83 (8_Supplement): Abstract nr LB220.
November, 2022

Optimized Multi-Attribute Method Workflow Addressing Missed Cleavages and Chromatographic Tailing/Carry-Over of Hydrophobic Peptides.

Kristensen DB, Ørgaard M, Sloth TM, Christoffersen NS, Leth-Espensen KZ, Jensen PF.
Analytical Chem. 2022 Dec 13;94(49):17195-17204. doi: 10.1021/acs.analchem.2c03820. Epub 2022 Nov 8.
February, 2022

First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.

Berlin J, Tolcher AW, Ding C, Whisenant JG, Horak ID, Wood DL, Nadler PI, Hansen UH, Lantto J, Skartved NJØ, Pedersen MW, Patnaik A.
Invest New Drugs. 2022 Jun;40(3):586-595. doi: 10.1007/s10637-022-01217-7. Epub 2022 Feb 3.
April, 2021

Characterization of Protein Glycoforms at Intact Level by Orbitrap Mass Spectrometry.

Kristensen DB, Sloth TM, Ørgaard M, Jensen PF.
Methods Mol Biol. 2021;2271:23-45. doi: 10.1007/978-1-0716-1241-5_2.
April, 2021

A human recombinant analogue to plasma-derived vaccinia immunoglobulin prophylactically and therapeutically protects against lethal orthopoxvirus challenge.

Parker S, D'Angelo J, Buller RM, Smee DF, Lantto J, Nielsen H, Jensen A, Prichard M, George SL
Antiviral Res. 2021 Nov;195:105179. doi: 10.1016/j.antiviral.2021.105179. Epub 2021 Sep 13
September, 2020

Phase I studies of Sym021, an anti-PD-1 antibody, alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)

Lakhani N, Spreafico A, Tolcher AW, Rodon J, Janku F, Chandana SR, Oliva M, Sharma M, Abdul-Karim RM, Hansen UH, Hansen L, Skartved NJØ, Poulsen TT, Nadal TP, Lantto J, Wood DL, Nadler PI, Siu LL
Annals of Oncology (2020) 31 (suppl_4): S645-S671. 10.1016/annonc/annonc279
August, 2020

Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype.

Lupo B, Sassi F, Pinnelli M, Galimi F, Zanella ER, Vurchio V, Migliardi G, Gagliardi PA, Puliafito A, Manganaro D, Luraghi P, Kragh M, Pedersen MW, Horak ID, Boccaccio C, Medico E, Primo L, Nichol D, Spiteri I, Heide T, Vatsiou A, Graham TA, Élez E, Argiles G, Nuciforo P, Sottoriva A, Dienstmann R, Pasini D, Grassi E, Isella C, Bertotti A, Trusolino L.
Sci Transl Med. 2020 Aug 5;12(555):eaax8313. doi: 10.1126/scitranslmed.aax8313.
July, 2020

Inter-laboratory study of an optimised peptide mapping workflow using automated trypsin digestion for monitoring monoclonal antibody product quality attributes.

Millán-Martín S, Jakes C, Carillo S, Buchanan T, Guender M, Kristensen DB, Sloth TM, Ørgaard M, Cook K, Bones J.Anal Bioanal Chem. 2020 Oct;412(25):6833-6848. doi: 10.1007/s00216-020-02809-z. Epub 2020 Jul 25.
Analytical Bioanalytical Chem. 2020 Oct;412(25):6833-6848. doi: 10.1007/s00216-020-02809-z. Epub 2020 Jul 25